This technology relates to methods for lowering a viral load of a virus where the virus causes a chronic viral infection and is resistant to an antiviral drug. The method comprises administering to a host a medicament comprising an antiviral drug to restrict the intracellular multiplication of the virus and that is capable of selecting for a predetermined antiviral drug-resistant mutation in a viral protein. The medicament further comprises a synthetic peptide that comprises the predetermined antiviral drug-resistant mutation and at least six amino acid residues flanking that mutation that are identical to the amino acid sequence of the viral protein of the antiviral drug-resistant virus. The synthetic peptide induces a cytotoxic T lymphocyte (CTL) response specific for cells infected with the antiviral drug-resistant virus. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved. Further, the compositions and methods of this technology are useful to target many viruses that can develop antiviral drug resistance, including HIV-1, HIV-2, hepatitis B virus, hepatitis C virus, and human herpesviruses.
- Therapeutic treatment using an antiviral drug in combination with a synthetic peptide for patients with viral infections
- Treatment to induce immune response in patients with drug resistance viral infections
- Applicable to a wide variety of infectious diseases
- Can be used in combination with antiviral drugs
Andrew T. Catanzaro, Jay A. Berzofsky (NCI)
- U.S. Patent Issued: U.S. Patent Number 9,474,793, Filed 20 Aug 2007, Issued 25 Oct 2016